scholarly article | Q13442814 |
P356 | DOI | 10.1001/ARCHINTE.162.10.1164 |
P8608 | Fatcat ID | release_3n7nwrhwy5dkfbbqozzbtcviwq |
P698 | PubMed publication ID | 12020188 |
P50 | author | Guillermo Ruiz-Irastorza | Q37830875 |
Beverley J Hunt | Q59165686 | ||
Graham R. V. Hughes | Q73300356 | ||
Munther A. Khamashta | Q73418907 | ||
P2093 | author name string | Maria J Cuadrado | |
Alejandro Escudero | |||
P433 | issue | 10 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | thrombosis | Q261327 |
antiphospholipid syndrome | Q582207 | ||
anticoagulation | Q63279445 | ||
P304 | page(s) | 1164-1169 | |
P577 | publication date | 2002-05-01 | |
P1433 | published in | JAMA Internal Medicine | Q177428 |
P1476 | title | Bleeding and recurrent thrombosis in definite antiphospholipid syndrome: analysis of a series of 66 patients treated with oral anticoagulation to a target international normalized ratio of 3.5. | |
P478 | volume | 162 |
Q95359426 | Q95359426 |
Q28174751 | A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS) |
Q92797128 | Acute ST-elevation myocardial infarction in a young patient with antiphospholipid syndrome |
Q73245534 | Antiphospholipid Antibody Syndrome |
Q59808719 | Antiphospholipid Syndrome and the Neurologist: From Pathogenesis to Therapy |
Q28192380 | Antiphospholipid antibodies in young adults with stroke |
Q41838557 | Antiphospholipid syndrome and recurrent thrombosis--limitations of current treatment strategies. |
Q38596401 | Antiphospholipid syndrome presenting as cerebral venous sinus thrombosis: a case series and a review |
Q38410376 | Antiphospholipid syndrome: an update |
Q37729831 | Antiphospholipid syndrome: frequency, main causes and risk factors of mortality |
Q40323287 | Apixaban for the Secondary Prevention of Thrombosis Among Patients With Antiphospholipid Syndrome: Study Rationale and Design (ASTRO-APS). |
Q35016262 | Association between CHADS₂risk factors and anticoagulation-related bleeding: a systematic literature review. |
Q33422184 | Bleeding and thrombosis in a patient with primary antiphospholipid syndrome using norethisterone: a case report |
Q35189299 | Cardiac disease in the antiphospholipid syndrome: recommendations for treatment. Committee consensus report |
Q28196276 | Cerebrovascular disease associated with antiphospholipid antibodies: more questions than answers |
Q37076800 | Controversies in the antiphospholipid syndrome: can we ever stop warfarin? |
Q37642830 | Current management of antiphospholipid syndrome-related thrombosis |
Q38818425 | Current status and future prospects for the treatment of antiphospholipid syndrome |
Q36947358 | D-dimer level and the risk for thrombosis in systemic lupus erythematosus |
Q24632951 | Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines |
Q34157396 | Heparin and osteoporosis during pregnancy: 2002 update |
Q45220914 | Homocysteine, antiphospholipid antibodies and risk of thrombosis in patients with systemic lupus erythematosus |
Q38856073 | IgG/IgM antiphospholipid antibodies present in the classification criteria for the antiphospholipid syndrome: a critical review of their association with thrombosis |
Q38273875 | Intensity of anticoagulation in the treatment of thrombosis in the antiphospholipid syndrome: a meta-analysis |
Q36458164 | Laboratory diagnosis and management challenges in the antiphospholipid syndrome |
Q47286340 | Low molecular weight heparin to prevent antiphospholipid syndrome morbidity in pregnancy |
Q46452620 | Management of end-stage renal disease patients with antiphospholipid antibody syndrome |
Q33423034 | Management of the antiphospholipid syndrome |
Q64910478 | Management of thrombotic and obstetric antiphospholipid syndrome: a systematic literature review informing the EULAR recommendations for the management of antiphospholipid syndrome in adults. |
Q28174728 | Moderate dose oral anticoagulant therapy in patients with the antiphospholipid syndrome? Yes |
Q90289969 | Multiple embolic strokes as a result of Libman-Sacks endocarditis associated with lupus and secondary antiphospholipid antibody syndrome: a case report |
Q39198671 | Pathogenesis and management of antiphospholipid syndrome |
Q40221778 | Patients with antiphosholipid syndrome and thrombotic recurrences: A real world observation (the Piedmont cohort study). |
Q64241805 | Prior Anticoagulation and Short- or Long-Term Clinical Outcomes in Ischemic Stroke or Transient Ischemic Attack Patients With Nonvalvular Atrial Fibrillation |
Q28071739 | Recommended Therapeutic INR Range for Patients with Antiphospholipid Syndrome on Warfarin Anticoagulation: Is Moderate-Intensity (INR 2.0 - 3.0) or High-Intensity (INR 3.1 - 4.0) Better for Reducing Risk of Recurrent Thromboembolic Events? |
Q90401929 | Risk factors for ischemic stroke in patients with non-valvular atrial fibrillation and therapeutic international normalized ratio range |
Q37477857 | Rituximab in lupus and beyond: the state of the art. |
Q36832526 | Role of complement in antiphospholipid antibody-mediated thrombosis |
Q35189292 | Stroke and the antiphospholipid syndrome: consensus meeting Taormina 2002. |
Q37543887 | Successful Anticoagulation Therapy for Antiphospholipid Syndrome with Mobile Aortic Thrombi |
Q37642828 | Thrombosis in systemic lupus erythematosus: risk and protection |
Q28193706 | Treatment and monitoring of patients with antiphospholipid antibodies and thrombotic history (Hughes syndrome) |
Q35621012 | Treatment of Thrombotic Antiphospholipid Syndrome: The Rationale of Current Management-An Insight into Future Approaches |
Q43342883 | Treatment of menorrhagia associated with oral anticoagulation: efficacy and safety of the levonorgestrel releasing intrauterine device (Mirena coil). |
Q35189289 | Venous thromboembolism in the antiphospholipid syndrome: management guidelines for secondary prophylaxis |
Q84600032 | [Antiphospholipid syndrome treatment, to whom, when and how long?] |
Search more.